Daiichi Sankyo is hiring a Medical Education Manager in Ontario - see the post! https://lnkd.in/eSa6U4xX
Daiichi Sankyo Canada
Pharmaceutical Manufacturing
Toronto, Ontario 484 followers
Passion for Innovation. Compassion for Patients.
About us
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops, and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need.
- Industry
- Pharmaceutical Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Toronto, Ontario
- Type
- Public Company
Locations
-
Primary
Get directions
Toronto, Ontario M5X 1A9 , CA
Employees at Daiichi Sankyo Canada
Updates
-
Daiichi Sankyo is hiring a Key Account Manager in Quebec - see the post! https://lnkd.in/ergwbvwP
Key Account Manager - QC
jobs.daiichi-sankyo.eu
-
Daiichi Sankyo is hiring a Key Account Manager in AB/SK - see the post. https://lnkd.in/gHw8MqZV
-
Daiichi Sankyo is hiring a Key Account Manager in ON - see the post. https://lnkd.in/gbRTynTZ
Key Account Manager - ON
jobs.daiichi-sankyo.eu
-
Daiichi Sankyo is hiring a Key Account Manager in BC/MB - see the post. https://lnkd.in/ggPGYeaw
Key Account Manager - BC
jobs.daiichi-sankyo.eu
-
Daiichi Sankyo Canada reposted this
Findings presented in Chicago at the annual meeting of the American Society of Clinical Oncology (ASCO) significantly broadened the range of breast cancer patients that could benefit from Enhertu, an antibody-drug conjugate designed to deliver toxic chemotherapy directly to tumours. The data showed an “unprecedented” improvement in progression-free survival, supporting the thesis that antibody-drug conjugates can deliver their payloads more specifically to cancer cells. AstraZeneca and Daiichi Sankyo Canada’s Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy – even if they had very low levels of the mutant protein targeted by the drug, according to trial results. Read more on this at: https://lnkd.in/dt7j7bhf Kim MacDonald #breastcancercanada #breastcancerresearch #breastcancerprogress #enhertu #ASCO24 #BCCatASCO24